Boehringer Ingelheim to acquire NBE-Therapeutics
Boehringer Ingelheim Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
14-Dec-2020 -
Boehringer Ingelheim announced the signing of a binding agreement for acquiring all shares of NBE-Therapeutics, a private, clinical-stage Swiss biotechnology company focused on antibody-drug conjugates and advancing targeted cancer therapies derived from its immune stimulatory iADC™ platform. ...
acquisitions
antibody-drug conjugate
Boehringer Ingelheim
+4